ArticleAntimicrobial agents and chemotherapy2012
Pharmacological inhibition of the ClpXP protease increases bacterial susceptibility to host cathelicidin antimicrobial peptides and cell envelope-active antibiotics.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- Role of ClpX and MsrA/B in the Oxidative and Cell Wall Stress Response in Bacillus anthracis Sterne.MicrobiologyOpen · 2026Article
- Differential contributions of ClpX and ClpP to pulmonary virulence in classical and hypervirulentInfection and immunity · 2026Article
- Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans.Nature communications · 2025Article
- Machine learning and genetic algorithm-guided directed evolution for the development of antimicrobial peptides.Journal of advanced research · 2025Article
- Gausemycin A-ResistantMicroorganisms · 2023Article
- Article
- ClpX/P-Dependent Degradation of Novel Substrates in Streptococcus mutans.Journal of bacteriology · 2022Article
- Proteolysis dependent cell cycle regulation in Caulobacter crescentus.Cell division · 2022Review
- DnaJ and ClpX Are Required for HitRS and HssRS Two-Component System Signaling in Bacillus anthracis.Infection and immunity · 2022Article
- Cellular functions of the ClpP protease impacting bacterial virulence.Frontiers in molecular biosciences · 2022Review
- Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.PloS one · 2022Article
- Cold Atmospheric-Pressure Plasma Caused Protein Damage in Methicillin-ResistantMicroorganisms · 2021Article
- β-Lactams against the Fortress of the Gram-PositiveChemical reviews · 2021Review
- Loss of the ClpXP Protease Leads to Decreased Resistance to Cell-Envelope Targeting Antimicrobials inFrontiers in microbiology · 2021Article
- Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria.Science advances · 2020Article
- Synthesis and Antichlamydial Activity of Molecules Based on Dysregulators of Cylindrical Proteases.Journal of medicinal chemistry · 2020Article
- Host Cathelicidin Exacerbates Group BmSphere · 2020Article
- Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.Scientific reports · 2020Article
- Innate Immune Interactions betweenFrontiers in cellular and infection microbiology · 2018Article
- Tetrazole-BasedAntimicrobial agents and chemotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The ClpXP protease is a critical bacterial intracellular protease that regulates protein turnover in many bacterial species. Here we identified a pharmacological inhibitor of the ClpXP protease, F2, and evaluated its action in Bacillus anthracis and Staphylococcus aureus. We found that F2 exhibited synergistic antimicrobial activity with cathelicidin antimicrobial peptides and antibiotics that target the cell well and/or cell membrane, such as penicillin and daptomycin, in B. anthracis and drug-resistant strains of S. aureus. ClpXP inhibition represents a novel therapeutic strategy to simultaneously sensitize pathogenic bacteria to host defenses and pharmaceutical antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.